JP2018512844A5 - - Google Patents

Download PDF

Info

Publication number
JP2018512844A5
JP2018512844A5 JP2017549280A JP2017549280A JP2018512844A5 JP 2018512844 A5 JP2018512844 A5 JP 2018512844A5 JP 2017549280 A JP2017549280 A JP 2017549280A JP 2017549280 A JP2017549280 A JP 2017549280A JP 2018512844 A5 JP2018512844 A5 JP 2018512844A5
Authority
JP
Japan
Prior art keywords
fragment
seq
nucleic acid
acid molecule
acne
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017549280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018512844A (ja
JP6840086B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/056179 external-priority patent/WO2016150926A1/en
Publication of JP2018512844A publication Critical patent/JP2018512844A/ja
Publication of JP2018512844A5 publication Critical patent/JP2018512844A5/ja
Application granted granted Critical
Publication of JP6840086B2 publication Critical patent/JP6840086B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017549280A 2015-03-20 2016-03-21 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント Active JP6840086B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15305414.3 2015-03-20
EP15305414 2015-03-20
PCT/EP2016/056179 WO2016150926A1 (en) 2015-03-20 2016-03-21 Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2018512844A JP2018512844A (ja) 2018-05-24
JP2018512844A5 true JP2018512844A5 (enExample) 2019-04-25
JP6840086B2 JP6840086B2 (ja) 2021-03-10

Family

ID=52807757

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549280A Active JP6840086B2 (ja) 2015-03-20 2016-03-21 薬物として、特に皮膚炎症性疾患において使用するためのフィブリノゲン由来の単離されたペプチドおよびそれらのフラグメント

Country Status (10)

Country Link
US (1) US10323078B2 (enExample)
EP (1) EP3270950B1 (enExample)
JP (1) JP6840086B2 (enExample)
CN (1) CN107636011B (enExample)
AU (1) AU2016236297B2 (enExample)
BR (1) BR112017020008A8 (enExample)
CA (1) CA2979812C (enExample)
DK (1) DK3270950T3 (enExample)
ES (1) ES2880795T3 (enExample)
WO (1) WO2016150926A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117304303B (zh) * 2023-07-14 2024-07-05 杭州恩和生物科技有限公司 纤连蛋白截短片段、组合物及用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0470974B1 (en) * 1989-04-10 2000-01-26 Helix BioMedix, Inc. Lytic peptides, use for growth, infection and cancer
US5639940A (en) * 1994-03-03 1997-06-17 Pharmaceutical Proteins Ltd. Production of fibrinogen in transgenic animals
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
CA2372700A1 (en) * 1999-06-30 2001-01-04 Regents Of The University Of California Diagnostic test for thrombotic or thromboembolic disease
EP1411964A4 (en) * 2001-07-06 2006-06-14 Oregon Health Science Universi PEPTIDES MODULATING BLOOD COAGULATION AND METHODS OF USE
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
AU2004232487A1 (en) * 2003-04-23 2004-11-04 Hansa Medical Ab Method for identifying an anti-streptococcal agent and its use for treating streptococcal infections
EP1941043B1 (en) * 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Method for the recombinant expression of a polypeptide
US20130280820A1 (en) * 2005-12-16 2013-10-24 Schering Corporation Biomarkers for psoriasis
WO2008019128A2 (en) * 2006-08-04 2008-02-14 Stb Lifesaving Technologies, Inc. Solid dressing for treating wounded tissue
EP2361930A3 (en) * 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
CN101618211A (zh) * 2008-07-03 2010-01-06 珠海联邦制药股份有限公司 一种乙肝多肽疫苗及其应用
EP2310411B2 (en) * 2008-07-09 2019-03-20 ProFibrix BV Recombinant fibrinogen
US20120052066A1 (en) 2008-11-07 2012-03-01 Cesar Calderon Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
EP4012714A1 (en) * 2010-03-23 2022-06-15 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
AU2012211537B2 (en) * 2011-02-02 2016-12-08 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Anti-carbamylated protein antibodies and the risk for arthritis

Similar Documents

Publication Publication Date Title
HRP20201973T1 (hr) Ligandi modificirani kružnom permutacijom kao agonisti i antagonisti
JP6981878B2 (ja) 抗菌療法
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
JP2008536483A5 (enExample)
WO2011036445A3 (en) Polypeptides and uses thereof
JP2015510393A5 (enExample)
JP2018520646A5 (enExample)
JP2018506286A5 (enExample)
JP2016526885A5 (enExample)
NZ587105A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
JP2016509011A5 (enExample)
JP2017532343A5 (enExample)
JP2017529326A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
JPWO2019156137A5 (enExample)
JP2018538356A5 (enExample)
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
CL2019003408A1 (es) Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407)
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
ATE500265T1 (de) Synthetische mecp2-sequenz für die proteinersatztherapie
JP2017039729A5 (enExample)
IL269187B1 (en) Dominant active yap, a hippo effector, induces chromatin accessiblity and cardiomyocyte renewal
WO2010103515A3 (en) Compositions and methods for prevention and treatment of neurodegenerative diseases
EP4282490A3 (en) Fibronectin-binding peptides for use in tumor or fibrosis diagnosis and therapy
JP2018512844A5 (enExample)